NAGENiagen Bioscience Inc

$423M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+37.4% YoY

Gross Profit

$18M62.5% margin

Operating Income

$7M24.4% margin

Net Income

$7M24.6% margin

EPS (Diluted)

$0.09

QoQ Revenue Growth

+13.9%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$9M

Stock-Based Comp.

$752,000

Balance Sheet

Total Assets

$68M

Total Liabilities

$22M

Stockholders' Equity

$46M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$21M	+37.4%
Gross Profit	$18M	$13M	+40.7%
Operating Income	$7M	-$168,000	+4332.7%
Net Income	$7M	$114,000	+6197.4%

NAGE Q4 2024 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena